Coegin Pharma

Hem
Sverige
Lund
Coegin Pharma

Vägbeskrivning Webbplats Kontakta affären

Kontaktinformation, kartor och vägbeskrivningar, kontaktformulär, öppettider, tjänster, betyg, foton, videor och meddelanden från Coegin Pharma, Bioteknikföretag, Scheeletorget 1, Lund.

We are a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin.

$COEGIN | NGM Growth Market & Börse Stuttgart

29/10/2026

Follicopeptide takes a major step into the hair transplantation market – with VEXIENNE CLINIC leading the way! 🌟

Coegin Pharma joins forces with Nordic Hair Clinic, Scandinavia’s largest hair transplant clinic, to introduce VEXIENNE CLINIC products, powered by Follicopeptide.

Commercial distribution through Nordic Hair Clinic starts already in 2026. In parallel, we will jointly develop and optimize specialized products and treatment routines, combining our peptide technology with Nordic Hair Clinic’s expertise in hair transplantation.

The hair transplantation market demands more than conventional cosmetic haircare. Follicopeptide brings something different: years of pharmaceutical research, extensive clinical development and unique peptide properties linked to hair follicle biology and the surrounding tissue environment.

Few cosmetic hair innovations can offer a comparable scientific foundation for this highly specialized market.

This agreement opens up a new commercial channel with significant potential for further international expansion.

🔗 Read our full press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-partners-with-scandinavia-s-largest-hair-trans-08866

28/10/2026

VEXIENNE is coming to MEDS!

We’ve signed a distribution agreement with MEDS, one of Sweden’s leading online pharmacies with over one million active customers, bringing VEXIENNE Hair Active X to a wider Swedish audience.

Powered by our clinically developed, non-hormonal Follicopeptide technology, VEXIENNE Hair Active X is a premium hair serum developed for thinning hair. The launch on MEDS is planned for mid-December, supported by dedicated marketing activities.

The agreement strengthens our Swedish pharmacy distribution as we continue to expand through established pharmacy, clinic and specialist partners across Europe.

Read the full press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-signs-distribution-agreement-with-meds-expan-23571

15/10/2026

A new era of sunless tanning is taking shape!

We are thrilled to report positive safety results for NPP-4, our next-generation peptide innovation with the potential to transform the global sunless tanning industry.

→ Positive preclinical safety evaluations
→ Positive clinical Patch and HRIPT studies
→ Patented peptide stabilization and delivery technology
→ Cost-effective production using our existing Follicopeptide® manufacturing platform

What makes NPP-4 different?

Conventional self-tanning products chemically color the skin’s surface. NPP-4 takes a fundamentally different approach, involving a novel peptide that is part of the skin’s natural pigmentation processes. The technology is being developed to support a naturally darker and more even-looking skin tone without UV exposure.

We see significant commercial opportunities for NPP-4 in the global sunless tanning market, with the potential to establish an entirely new premium product category.

🔗 Link to the full press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-reports-positive-npp-4-safety-results-advanc-48766

30/09/2026

We are putting greater commercial resources behind Follicopeptide and VEXIENNE. ✨

We have spent the past few months building the foundation for a larger commercial business around Follicopeptide. Today, we have scalable production capacity, VEXIENNE in the market and a Follicopeptide-based product portfolio that continues to grow.

More pieces are coming together, and now it’s about ex*****on:

→ Expanding sales and distribution
→ Increasing our efforts in marketing and communication
→ Preparing for the launch of our new eyelash product
→ Continuing the commercialization of VEXIENNE CLINIC – our dedicated series for professional clinics and hair transplant clinics
→ Pursuing opportunities across retail and international partnerships

To support this next phase, we have called SEK 6 million under our previously announced capital facility. The facility gives us an efficient and flexible way to access capital as needed. It also provides additional resources to accelerate our commercial activities around Follicopeptide and VEXIENNE.

A special thank you to our long-term major shareholders for making this solution possible – and for their continued confidence in Coegin and our commercial ambitions.

Read the full press release:
https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-calls-sek-6-million-under-previously-announced-34404

08/09/2026

Could Follicopeptide redefine the future of lash serums?

We have completed a 56-day clinical study of Follicopeptide Lash Gel Serum, showing both early visible effects and statistically significant results in eyelashes:

→ Visible effects reported by almost one-third of participants within two weeks
→ Statistically significant increase in eyelash length after both 42 and 56 days
→ Confirmed by two separate instrumental measurement methods
→ Excellent tolerability around the eyes under ophthalmological control

For us, this is not simply about adding another lash serum. It adds important clinical evidence in the eyelash category and supports the broader commercial potential of Follicopeptide as a prostaglandin-free peptide technology across hair, lashes and brows.

Read more in our press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-reports-strong-clinical-results-for-follicopep-10147

19/08/2026

📄 Our Q2 report is now available.

Less than a year ago, we were preparing our first commercial production of Follicopeptide. Today, we have products on the market, our own production capability, international private label partners, our own VEXIENNE brand, access to major beauty retailers, encouraging user feedback, and an expanding product portfolio.

We have spent years building the innovation and the last quarters building the commercial platform. Our focus now is to turn that platform into growth.

🔗 Link to the report:https://cdn.bequoted.com/media/1/08a6d90d-a570-49c0-a259-329157084b01/Coegin-Pharma-Interim-Report-Q2-2026.pdf

18/08/2026

Follicopeptide is expanding – opening new opportunities in hair and beauty ✨

Our product portfolio is growing with new beauty and professional applications:
⭐️ VEXIENNE Eyelash Serum – Q4 2026
⭐️ A unique Follicopeptide spray developed specifically for hair transplant clinics – Q1 2027
⭐️ VEXIENNE Clinic – a new professional portfolio for clinics, health spas and hair specialists – Q1 2027
⭐️ Follicopeptide Eyebrow product – Q1 2027

And we are already seeing encouraging early signs from our eyelash development. Our 8-week consumer panel in Sweden and Denmark is ongoing, with positive early feedback after four weeks, alongside an ongoing 8-week clinical testing. Take a look at the Day 1 vs Day 33 example below for an early glimpse of the progress we are seeing. 👀

For us, this is about much more than individual product launches. We are building Follicopeptide into a broader commercial platform across beauty, professional hair care and clinics.

More products. More channels. More opportunities – for us and for our partners. ✨

Read our full press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-provides-an-update-on-product-development-and-05878

25/06/2026

Today, our principal shareholders reaffirmed their confidence in Coegin by committing additional capital to support our continued commercialization and growth.

The financing solution combines a directed issue of approximately SEK 6.3 million with a capital facility providing access to an additional SEK 16 million, strengthening our financial flexibility through 2026–2027.

By combining a limited directed issue with a flexible capital facility from committed long-term shareholders, the financing provides the resources needed to execute our commercial strategy while promoting capital efficiency, minimizing financing costs and supporting long-term shareholder alignment.

This allows us to focus on:�✔️ Scaling production capacity�✔️ Accelerating commercial expansion�✔️ Supporting our growing network of partners�✔️ Driving towards positive cash flow

💬 Johan Arver, Alveco Invest AB:
"The Board has proposed a financing solution that we, as a principal shareholder, have chosen to fully support. We are not investing defensively – we are investing to accelerate growth. The Company has transitioned from development to commercialization, with innovations that stand out internationally and a highly scalable business model. We believe in the Company, we believe in the management team, and we see strong prospects for achieving positive cash flow within a foreseeable future."

As we continue executing our commercial strategy and delivering on our plans, we thank Alveco Invest AB, Crystallus AB, Bengt Svenstig and Lennart Börjesson for their continued confidence in Coegin Pharma.

Read more in our press release:

16/06/2026

Partner expansion is the strongest validation. 💥

Today we announced highly encouraging feedback from Harklinikken, one of the world's leading providers of science-led hair and scalp treatments.

Following a 16-week customer evaluation, participants reported reduced hair shedding, higher hair density, and the perception of thicker, fuller-looking hair. Many experienced noticeable improvements within the first 8 weeks of daily use.

Most importantly, Hårklinikken is now preparing a broader commercial launch of Follicopeptide-based products across its clinics in the US, Europe and the Middle East during the second half of 2026.

For us, this is another important step in the commercial journey of Follicopeptide. Strong science is important. Commercial ex*****on is what creates value. Seeing a respected global clinic brand expand its commitment strengthens our confidence in the long-term international opportunity.

🌍 From Scandinavia to international markets.
🔬 Built on clinically developed peptide science.
📈 Driven by growing partner demand.

The momentum continues.

Read the full press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-receives-highly-encouraging-user-feedback-from-60226

15/06/2026

VEXIENNE × LYKO ✨

This July, LYKO will launch Hair Active X, powered by our proprietary Follicopeptide technology, under the VEXIENNE brand.

With annual sales approaching SEK 4 billion, more than 30 stores, and operations across seven European markets, LYKO has established itself as one of Northern Europe’s leading beauty retailers and an attractive platform for innovative beauty brands.

🔗 Read our full press release: https://www.coeginpharma.com/investor-relations/press-releases/?slug=coegin-pharma-enters-distribution-agreement-with-lyko-for-la-41005

Adress

Scheeletorget 1
Lund
22363

Webbplats

https://www.coeginpharma.com/, https://www.coeginpharma.com/en/privacy-policy/

Aviseringar

Bli först med att veta: vi skickar ett mejl när Coegin Pharma publicerar nyheter och kampanjer. Din e-postadress används inte till något annat, och du kan avsluta prenumerationen när som helst.